

1. E. Ota, M. Takeiri, M. Tachibana, Y. Ishikawa, K. Umezawa and S. Nishiyama: Synthesis and biological evaluation of molecular probes based on the 9-methylstreptimidone derivative DTCM-glutarimide. *Bioorganic & Medicinal Chemistry Letters* 22: 164-167, 2012.
2. T. Fukushima, M. Kawaguchi, K. Yorita, H. Tanaka, K. Umezawa and H. Kataoka: Antitumor effect of dehydroxymethylepoxyquinomicin (DHMEQ), a small molecule inhibitor of nuclear factor- $\kappa$ B, on glioblastoma. *Neuro-Oncology* 14: 19-28, 2012.
3. H. Hosoi, N. Kawai, H. Hagiwara, T. Suzuki, A. Nakazaki, K. Takao, K. Umezawa and S. Kobayashi: Determination of the absolute structure of (+)-akaterpin. *Chem. Pharm. Bull.* 60: 137-143, 2012.
4. R. Saito, S. Yamada, Y. Yamamoto, T. Kodera, A. Hara, Y. Tanaka, F. Kimura, I. Takei, K. Umezawa and I. Kojima: Conophylline suppresses pancreatic stellate cells and improves islet fibrosis in Goto-Kakizaki rats. *Endocrinology* 153: 621-630, 2012.
5. M. Takeiri, K. Horie, D. Takahashi, M. Watanabe, R. Horie, S. Simizu and K. Umezawa: Involvement of DNA binding domain in the cellular stability and importin affinity of NF- $\kappa$ B component RelB. *Org. Biomol. Chem.* 10: 3053-3059, 2012.
6. T. Funakoshi, K. Yamashita, N. Ichikawa, M. Fukai, T. Suzuki, R. Goto, T. Oura, N. Kobayashi, T. Katsurada, S. Ichihara, M. Ozaki, K. Umezawa, and S. Todo: A novel NF- $\kappa$ B inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice. *Journal of Crohn's and Colitis* 6: 215-225, 2012.
7. T. Yasukagawa, Y. Niwa, S. Simizu and K. Umezawa: Suppression of cellular invasion by glybenclamide through inhibited secretion of platelet-derived growth factor in ovarian clear cell carcinoma ES-2 cells. *FEBS Lett.* 586:1504–1509, 2012.
8. 梅澤一夫：細胞内シグナル伝達分子と創薬。新しい薬学事典 pp110-113, 朝倉書店 2012.6.25
9. N. Noma, S. Simizu, Y. Kambayashi, Y. Kabe, M. Suematsu, and K. Umezawa: Involvement of NF- $\kappa$ B-mediated expression of galectin-3-binding protein in tumor necrosis factor- $\alpha$ -induced breast cancer cell adhesion. *Oncology Reports* 27: 2080-2084,

2012.

10. Y. Niwa, C. Matsui, N. Sukumwang, H. Inuma, Y. Ikeda, T. Koyano, T. Kovitayakorn, S. Simizu and K. Umezawa: Inhibition of lysenin-induced hemolysis by all-*E*-lutein derived from the plant *Dalbergia latifolia*. *Planta Medica* 78: 957-961, 2012.

11. M. Kawata, D. Koinuma, T. Ogami, K. Umezawa, C. Iwata, T. Watabe and K. Miyazono: TGF- $\beta$ -induced epithelial-mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by proinflammatory cytokines derived from RAW 264.7 macrophage cells. *J. Biochem.* 151: 205-216, 2012.

12. R. Goto, K. Yamashita, T. Aoyagi, S. Ueki, M. Uno, T. Oura, N. Kobayashi, R. Igarashi, S. Shibasaki, K. Wakayama, G. Hirokata, T. Shibata, K. Umezawa, M. Ozaki, and S. Todo: The immunomodulatory effect of nuclear factor- $\kappa$ B inhibition by dehydroxymethylepoxyquinomicin in combination with donor-specific blood transfusion. *Transplantation* 93: 777-786, 2012.

13. N. Lampiasi, A. Azzolina<sup>1</sup>, K. Umezawa, G. Montalto, J. A. McCubrey and M. Cervello: The novel NF- $\kappa$ B inhibitor DHMEQ synergizes with Celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. *Cancer Lett.* 322: 35-44, 2012.

14. K. Hinohara, S. Kobayashi, S. Simizu, K. Tada, E. Tsuji, K. Nishioka, K. Umezawa, M. Mori, H. Kanauchi, T. Ogawa, J. Inoue, A. Tojo and N. Gotoh: ErbB receptor tyrosine kinase/NF- $\kappa$ B signaling controls mammosphere formation in human breast cancer. *Proc. Natl. Acad. Sci. USA* 109: 6584-6589, 2012.

15. K. Shimizu, S. Konno, M. Ozaki, K. Umezawa, K. Yamashita, S. Todo and M. Nishimura: Dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-kappaB inhibitor, inhibits allergic inflammation and airway remodelling in murine models of asthma. *Clin. Exp. Allergy* 42: 1273–1281, 2012.

16. A. Kaneda, S. K. Gantsev and K. Umezawa: Inhibition of cellular invasion and induction of anoikis in mouse melanoma cells by an anti-inflammatory agent DTCM-glutarimide. *Creative Surgery and Oncology* 2012: 4-9, 2012.

17. M. Takeiri, E. Ota, S. Nishiyama, H. Kiyota, S. Simizu and K. Umezawa: Structure-activity relationship of 9-methylstreptimidone that induces selective apoptosis in adult T-cell leukemia cells. *Oncology Res.* 20: 7-14, 2012.
18. M. S. Brassesco, J. A. Pezuk, A. G. Morales, J. C. de Oliveira, E. T. Valera, G. N. da Silva, H. F. de Oliveira, C. A. Scrideli, K. Umezawa, L. G. Tone: Cytostatic *in vitro* effects of DTCM-glutarimide on bladder carcinoma cells. *Asian Pacific Journal of Cancer Prevention* 13: 1957-1962, 2012.
19. M. Nakayama, Y. Niki, T. Kawasaki, Y. Takeda, K. Horiuchi, A. Sasaki, Y. Okada, K. Umezawa, H. Ikegami, Y. Toyama and T. Miyamoto: Enhanced susceptibility to lipopolysaccharide-induced arthritis and endotoxin shock in interleukin-32 alpha transgenic mice through induction of tumor necrosis factor alpha. *Arthritis Research & Therapy* 14:R120 <http://arthritis-research.com/content/14/3/R120>, 2012.
20. R. Kobayashi, K. Hanaya, M. Shoji, K. Umezawa and T. Sugai: A chemo-enzymatic expeditious route to racemic dihexanoyl (2*R*\*,3*R*\*,4*R*\*)-dehydroxymethylepoxyquinomycin (DHMEQ), the precursor for lipase-catalyzed synthesis of the potent NF- $\kappa$ B Inhibitor, (2*S*,3*S*,4*S*)-DHMEQ. *Chemical and Pharmaceutical Bulletin* 60: 1220-1223, 2012.
21. C. Alberti, P. Pinciroli, B. Valeri, R. Ferri, A. Ditto, K. Umezawa, M. L. Sensi, S. Canevari, and A. Tomassetti: Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via NF $\kappa$ B pathway on advanced-stage epithelial ovarian cancer. *Oncogene* 31: 4139-4149, 2012.
22. A. M. Castro-Gamero, K. S. Borgesa, V. da Silva Silveira, R. C. P. Lira, R. de Paula G. Queiroz, F. C. P. Valera, C. A. Scrideli, K. Umezawa and L. G. Tone: Inhibition of nuclear factor- $\kappa$ B by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells. *Anti-Cancer Drugs* 2012: 638-650, 2012.
23. F. C.P. Valera, K. Umezawa, M. S. Brassesco, A. M. C. Gamero, R. G. P. Queiro, C. A. Scrideli, L. G. Tone, W. T. Anselmo-Lima: Suppression of inflammatory cytokine secretion by an NF- $\kappa$ B inhibitor in nasal polyps fibroblasts. *Cellular Physiology and*

Biochemistry 30: 13-22, 2012.

24. N. Kozakai, E. Kikuchi, M. Hasegawa, E. Suzuki, H. Ide, A. Miyajima, Y. Horiguchi, J. Nakashima, K. Umezawa, N. Shigematsu and M. Oya: Enhancement of radiosensitivity by a unique novel NF- $\kappa$ B inhibitor, DHMEQ, in prostate cancer. *British J. Cancer* 107: 652-657, 2012.

25. Y. Niwa, T. Suzuki, N. Dohmae, K. Umezawa and S. Simizu: Determination of cathepsin V activity and intracellular trafficking by N-glycosylation. *FEBS Lett.* 586: 3601–3607, 2012.

26. M. Nishimura, T. Nii, G. Trimova, S. Miura, K. Umezawa, A. Ushiyama, T. Kubota: The NF- $\kappa$ B specific inhibitor DHMEQ prevents thrombosis formation in a mouse model of antiphospholipid syndrome. *J. Nephropathology* 2 (2):114-121, 2013.

27. T. Shimo, Y. Adachi, S. Yamanouchi, S. Tsuji, T. Kimata, K. Umezawa, M. Okigaki, J. Takaya, S. Ikehara, K. Kaneko: A novel NF- $\kappa$ B inhibitor DHMEQ ameliorates puromycin aminonucleoside induced nephrosis in mice. *Am. J. Nephrol.* 37: 302–309, 2013.

28. A. Ogasawara, S. Simizu, A. Ito, T. Kawai, Y. Saisho, I. Takei and K. Umezawa: Inhibition of NO-induced  $\beta$ -cell death by novel NF- $\kappa$ B inhibitor (-)-DHMEQ via activation of Nrf2-ARE pathway. *Biochem. Biophys. Chem. Commun.* 433: 181–187, 2013.

29. K. Sidthipong, S. Todo, I. Takei, I. Kojima and K. Umezawa: Screening of new bioactive metabolites for diabetes therapy (Review). *Intern. Emerg. Med.* 8 (Suppl 1): S57-S59, 2013.

30. S. Shibasaki, K. Yamashita, R. Goto, K. Wakayama, Y. Tsunetoshi, M. Zaito, R. Igarashi, S. Haga, M. Ozaki, K. Umezawa and S. Todo: Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway. *Transplantation* 95: 542-550, 2013.

31. K. Suzuki, K. Aiura, S. Matsuda, O. Itano, O. Takeuchi, K. Umezawa, and Y. Kitagawa: Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a

mouse model of liver metastasis of pancreatic cancer. *Clinical & Experimental Metastasis* 30:381-392, 2013.

32. Y. Arai, H. Inuma, Y. Ikeda, M. Igarashi, K. Hatano, N. Kinoshita, T. Ukaji, S. Simizu and K. Umezawa: Migracins A and B, new inhibitors of cancer cell migration, produced by *Streptomyces* sp. *J. Antibiot.* 66: 225–230, 2013.

33. M. S. Brassesco, J. A. Pezuk, J. C. de Oliveira, E. T. Valera, H. F. de Oliveira, C. A. Scrideli, K. Umezawa and L. G. Tone: Activator Protein-1 Inhibition by 3-[(dodecylthiocarbonyl)methyl]-glutamaride impairs invasion and radiosensitizes osteosarcoma cells in vitro. *Cancer Biotherapy and Radiopharmaceuticals* 28: 351-358, 2013.

34. M. S. Brassesco, G. Roberto, A. Morales, J. de Oliveira, L. E. Delsin, J. A. Pezuk, E. T. Valera, C. G. Carlotti Jr., E. M. Rego, H. F. de Oliveira, C. A. Scrideli, K. Umezawa and L. G. Tone: Inhibition of NF- $\kappa$ B by dehydroxymethylepoxyquinomicin suppresses invasion and synergistically potentiates Temozolomide and  $\gamma$ -radiation cytotoxicity in glioblastoma cells. *Chemotherapy Research and Practice*, Volume 2013 Article ID 593020 (16 pages), 2013.

35. K. Umezawa: Peritoneal NF- $\kappa$ B as a Possible molecular target for suppression of various cancers and inflammation. (Review) *Forum of Immunopathological Diseases and Therapeutics* 4: 63-77, 2013.

36. S. Nakajima, H. Kato, L. Gu, S. Takahashi, H. Johno, K. Umezawa and M. Kitamura: Pleiotropic potential of dehydroxymethylepoxyquinomicin for NF- $\kappa$ B suppression via reactive oxygen species and unfolded protein response. *J. Immunol.* 190: 6559-6569, 2013.

37. M. Kassan, S. K. Choi, M. Galán, A. Bishop, K. Umezawa, M. Trebak, K. Matrougui: NF $\kappa$ B impairs vascular function through PARP-1, SP-1 and COX2-dependent mechanisms in type 2 diabetes. *Diabetes* 62: 2078-2087, 2013.

38. T. Ohsugi, T. Ishida, T. Shimasaki, S. Okada and K. Umezawa: p53 dysfunction precedes the activation of nuclear factor- $\kappa$ B during disease progression in mice

expressing Tax, a human T-cell leukemia virus type 1 oncoprotein. *Carcinogenesis* 34: 2129-2136, 2013.

39. M. Kuroda, S. Funasaki, T. Saitoh, Y. Sasazawa, S. Nishiyama, K. Umezawa and S. Simizu: Determination of topological structure of ARL6ip1 in cells: Identification of the essential binding region of ARL6ip1 for conophylline. *FEBS Letters* 587: 3656-3660, 2013.

40. T. Togano, M. Nakashima, M. Watanabe, K. Umezawa, T. Watanabe, M. Higashihara and R. Horie: Synergistic effect of 5-azacytidine and NF-kappa B inhibitor DHMEQ on apoptosis induction in myeloid leukemia cells. *Oncology Res.* 20: 571-577, 2013.

41. N. Sukumwang and K. Umezawa: Earthworm-derived pore-forming toxin Lysenin and screening of its inhibitors. *Toxins* 5: 1392-1401, 2013.

42. T. Ukaji, S. Gantsev and K. Umezawa: Inhibition of Cancer cell invasion and metastasis by NF-kappa B inhibitors. (Review) *Creative Surgery and Oncology* 2013 (3): 6-12, 2013.

43. S. K. Gantsev, K. Umezawa, D. V. Islamgulov, E. K. Husnutdinova, R. S. Ishmuratova, V. Y. Frolova, S. R. Kzyrgalin: The role of inflammatory chemokines in lymphoid neorganogenesis in breast cancer. *Biomedicine & Pharmacotherapy* 67: 363-366, 2013.

44. D. Kuraya, M. Watanabe, Y. Koshizuka, M. Ogura, T. Yoshida, Y. Asahi, H. Kamachi, T. Nakamura, H. Harashima, M. Ozaki, K. Umezawa, M. Matsushita, K. Yamashita, and S. Todo: Efficacy of DHMEQ, a NF- $\kappa$ B Inhibitor, in islet transplantation: I. HMGB1 suppression by DHMEQ prevents early islet graft damage. *Transplantation* 96: 445-453, 2013.

45. H. Kono, K. Nakagawa, S. Morita, K. Shinoda, R. Mizuno, E. Kikuchi, A. Miyajima, K. Umezawa and M. Oya: Effect of a novel nuclear factor kappaB activation inhibitor on renal ischemia reperfusion injury. *Transplantation* 96: 863-870, 2013.

46. S. Shimogaki, S. Ito, S. Komatsu, R. Koike, N. Miyasaka, K. Umezawa and T.

Kubota: Inhibition of the NF- $\kappa$ B pathway as a candidate therapeutic strategy for cryopyrin-associated periodic syndrome. *Mod. Rheumatol.* 24: 517-524. doi: 10.3109/14397595.2013.844298. Epub 2013 Nov 4.

47. M. Watanabe, K. Yamashita, H. Kamachi, D. Kuraya, Y. Koshizuka, S. Shibasaki, Y. Asahi, H. Ono, S. Emoto, M. Ogura, T. Yoshida, M. Ozaki, K. Umezawa, M. Matsushita and S. Todo: Efficacy of DHMEQ, a NF- $\kappa$ B inhibitor, in islet transplantation: II. Induction DHMEQ treatment ameliorates subsequent alloimmune responses and permits long-term islet allograft acceptance. *Transplantation* 96: 454-462, 2013.

48. 梅澤一夫 : 糖尿病治療に有用なシグナル伝達阻害剤の探索と分子デザイン。 Screening and molecular design of signal transduction inhibitors for diabetes therapy. *日本糖尿病眼学会誌* 18: 13-19, 2013.

49. N. Kubo, R. Saito, K. Hamano, M. Nagasawa, F. Aoki, I. Takei, K. Umezawa, H. Kuwano and I. Kojima: Conophylline suppresses hepatic stellate cells and attenuates thioacetamide-induced liver fibrosis in rats. *Liver International* 2013, DOI: 10.1111/liv.12328.

50. T. Ukaji, Y. Sasazawa, K. Umezawa and S. Simizu: Involvement of conserved tryptophan residues for secretion of TIMP-2. *Oncology Letters* 7: 631-634, 2014.

51. T. Togano, M. Watanabe, K. Itoh, K. Umezawa, N. Masuda, M. Higashihara and R. Horie: Activation of Akt involves resistance to NF- $\kappa$ B inhibition and abrogation of both triggers synergistic apoptosis in lung adenocarcinoma cells. *Lung Cancer* 83: 139-145, 2014.

52. M. Watanabe, K. Umezawa, M. Higashihara and R. Horie: Combined inhibition of NF- $\kappa$ B and Bcl-2 triggers synergistic reduction of viability and induces apoptosis in melanoma cells. *Oncology Res.* 21: 173-180, 2014.

53. Y. Goto, Y. Niwa, T. Suzuki, N. Dohmae, K. Umezawa and S. Simizu: C-mannosylation of human hyaluronidase 1: Possible roles for secretion and enzymatic activity. *International J. Oncology* 45: 344-350, 2014.

54. M. El-Salhy, K. Umezawa, O.-H. Gilja, J. G. Hatlebakk, D. Gundersen and T. Hausken: Amelioration of severe TNBS induced colitis by novel AP-1 and NF- $\kappa$ B inhibitors in rats. *The Scientific World* Volume 2014 Article ID 813804 (8 pages)
55. M. Celegato, C. Borghese, K. Umezawa, N. Casagrande, A. Colombatti, A. Carbone, and D. Aldinucci: The NF- $\kappa$ B inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma. *Cancer Letters* 349: 26-34, 2014.
56. H. Nishio, T. Yaguchi, J. Sugiyama, H. Sumimoto, K. Umezawa, T. Iwata, N. Susumu, T. Fujii, N. Kawamura, A. Kobayashi, J-H Park, D. Aoki, Y. Kawakami: Immunosuppression through constitutively activated NF- $\kappa$ B signaling in human ovarian cancer and its reversal by a NF- $\kappa$ B inhibitor. *British J. Cancer* 110: 2965-2974, 2014.
57. M. Sato, K. Nakanishi, S. Haga, M. Fujiyoshi, M. Baba, K. Mino, Yimin, H. Niwa, H. Yokoo, K. Umezawa, Y. Ohmiya, T. Kamiyama, S. Todo, A. Taketomi and M. Ozaki: Anoikis induction and inhibition of peritoneal metastasis of pancreatic cancer cells by a nuclear factor-kappa B inhibitor, (-)-DHMEQ. *Oncology Res.* 21: 333-343, 2014..
58. T. Ukaji and K. Umezawa: Novel approaches to target NF- $\kappa$ B and other signaling pathways in cancer stem cells. *Advances in Biological Regulation* 56: 108-115, 2014.
59. N. Koide, Y. Kondo, E. Odkhuu, J. Ulziisaikhan, T. Ukaji, T. Yokochi and K. Umezawa: Inhibition of receptor activator of nuclear factor- $\kappa$ B ligand (RANKL) or lipopolysaccharide-induced osteoclast formation by conophylline (CNP) through downregulation of CREB. *Immunology Letters* 161: 31-37, 2014.
60. C. Matsui, Y. Ikeda, H. Iinuma, N. Kushida, T. Kunisada, S. Simizu and K. Umezawa: Isolation of a novel paxilline analog pyrapaxilline from fungus that inhibits LPS-induced NO production. *J. Antibiotics* 67: 787-790, 2014.
61. S. Haga, T. Ozawa, Y. Yamada, N. Morita, I. Nagashima, H. Inoue, Y. Inaba, N. Noda, R. Abe, K. Umezawa and M. Ozaki: p62/SQSTM1 plays a protective role in oxidative injury of steatotic liver in a mouse hepatectomy model. *Antioxidants and Redox Signaling* 18: 2515-2530, 2014.



62. N. Lampiasi, K. Umezawa, G. Montalto, M. Cervello: Poly (ADP-Ribose) polymerase inhibition synergizes with the NF- $\kappa$ B inhibitor DHMEQ to kill hepatocellular carcinoma cells. *BBA - Molecular Cell Research* 1843: 2662-2673, 2014.
63. T. Miyagi, B. Shiotani, R. Miyoshi, T. Yamamoto, T. Oka, K. Umezawa, T. Ochiya, M. Takano and H. Tahara: DSE-FRET: A new anti-cancer drug screening assay for DNA binding proteins. *Cancer Science* 105: 870-874, 2014.
64. W. Seubwai, R. Kraiklang, K. Vaeteewoottacharn, K. Umezawa, S. Okada, S. Wongkham: Aberrant expression of NF- $\kappa$ B in liver fluke associated cholangiocarcinoma: implications for targeted therapy. *PLOS ONE* 9 (8): e106056, 2014.
65. M. Kamoshita, Y. Ozawa, S. Kubota, S. Miyake, C. Tsuda, N. Nagai, K. Yuki, S. Shimmura, K. Umezawa and K. Tsubota. AMPK-NF- $\kappa$ B axis in the photoreceptor disorder during retinal inflammation. *PLoS One* 9 (7): e103013, 2014.
66. S. Heavey, P. Godwin, A.-M. Baird, M. P. Barr, K. Umezawa, S. Cuffe, S. P. Finn, K. J. O'Byrne and K. Gately: Strategic targeting of the PI3K-NF $\kappa$ B axis in cisplatin-resistant NSCLC. *Cancer Biology & Therapy* 15: 1367-1377, 2014..
67. S. Inokawa, T. Watanabe, H. Keino, Y. Sato, A. Hirakata, A. A. Okada, K. Fukuda, A. Fukushima and K. Umezawa: Dehydroxymethylepoxyquinomicin, a novel nuclear factor- $\kappa$ B inhibitor, reduces chemokines and adhesion molecule expression induced by IL-1 $\beta$  in human corneal fibroblasts. *Graefes Arch. Clin. Exp. Ophthalmol.* 253: 557-563, 2015
68. M. Kuboki, A. Ito, S. Simizu and K. Umezawa: Activation of apoptosis by caspase-3-dependent specific RelB cleavage in anticancer agent-treated cancer cells: Involvement of positive feedback mechanism. *Biochem. Biophys. Res. Commun.* 456: 810-814, 2015.
69. N. Koide, A. Kaneda, T. Yokochi and K. Umezawa: Inhibition of RANKL- and LPS-induced osteoclast differentiations by novel NF- $\kappa$ B inhibitor DTCM-glutarimide. *International Immunopharmacology* 25: 162-168, 2015.

70. K. Horie, J. Ma and K. Umezawa: Inhibition of canonical NF- $\kappa$ B nuclear localization by (-)-DHMEQ via impairment of DNA binding. *Oncology Res.* 22: 105-115, 2015.
71. N. Noma, M. Asagiri, M. Takeiri, S. Ohmae, K. Takemoto, K. Iwaisako, S. Simizu and K. Umezawa: Inhibition of MMP-2-mediated mast cell invasion by NF- $\kappa$ B inhibitor DHMEQ in mast cells. *International Archives of Allergy and Immunology* 166: 84-90, 2015.
72. J. C. Mbongue, D. Nicholas, K. Zhang, B. N. Hamilton, M. Larios, G. Zhang, K. Umezawa, A. Firek and W. H. R. Langridge: Induction of indoleamine 2, 3 dioxygenase in human dendritic cells by a cholera toxin B subunit - Proinsulin vaccine. *PLOS ONE* DOI: 10.1371/journal.pone.0118562, 2015.
73. Y. Sasazawa, N. Sato, K. Umezawa and S. Simizu: Conophylline protects cells in cellular models of neurodegenerative diseases by inducing mTOR-independent autophagy. *J. Biol. Chem.* 290: 6168-6178, 2015.
74. Y. Ito, E. Kikuchi, N. Tanaka, T. Kosaki, E. Suzuki, R. Mizuno, T. Shinojima, A. Miyajima, K. Umezawa and M. Oya: Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer. *BMC Cancer* 2015 15:324. DOI: 10.1186/s12885-015-1315-9. Open access.
75. S. Yamanouchi, Y. Adachi, T. Shimo, K. Umezawa, M. Okigaki, S. Tsuji, M. Li, J. Takaya, T. Kuge, S. Ikehara, K. Kaneko: A nuclear factor- $\kappa$ B inhibitor, dehydroxymethylepoxyquinomicin, ameliorates GVHD in allogeneic bone marrow transplantation. *Immunobiology* 220: 1059-1066, 2015.
76. M. Zaitse, K. Yamashita, S. Shibasaki, Y. Tsunetoshi, M. Fukai, M. Ogura, T. Yoshida, R. Igarashi, N. Kobayashi, K. Umezawa and S. Todo: 3-[(dodecylthiocarbonyl)methyl]-glutarimide attenuates graft arterial disease by suppressing alloimmune responses and vascular smooth muscle cell proliferation. *Transplantation* 99: 948-956, 2015. doi: 10.1097/TP.576.
77. T. Toda, M. Watanabe, J. Kawato, M. Higashihara, T. Kunisada, K. Umezawa and

R. Horie: Brefeldin A exerts differential effects on anaplastic lymphoma kinase positive anaplastic large cell lymphoma and Hodgkin lymphoma cell lines. *British J. Haematology* 170: 837-846, 2015.

78. T. F. S. Ali, K. Iwamura, H. I. Ciftci, R. Koga, M. Matsumoto, Y. Oba, H. Kurosaki, M. Fujita, Y. Okamoto, K. Umezawa, M. Nakao, T. Hide, K. Makino, J. Kuratsu, M. Abdel-Aiziz, G. El-Din, A. A. Abuo-Rahma, E. A. M. Beshr and M. Otsuka: Novel metal chelating molecules with anticancer activity. Striking effect of the imidazole substitution of the histidine–pyridine– histidine system. *Bioorg. Med. Chem.* 23: 5476-5482, 2015.

79. T. Ukaji, Y. Lin, K. Banno, S. Okada and K. Umezawa: Inhibition of IGF-1-mediated cellular migration and invasion by migracin A in ovarian clear cell carcinoma cells. *PLOS One* 10(9): e0137663, 2015 DOI:10.1371/journal.pone.0137663.

80. G. Malaponte, S. S. Signorelli, V. Bevelacqua, J. Polesel, M. Tadorelli, C. Guarneri, C. Fenga, K. Umezawa, and M. Libra: Increased levels of NF- $\kappa$ B-dependent markers in cancer-associated deep venous thrombosis. *PLOS One.* 2015; 10(7): e0132496.

81. L. Wang, Y. Lin, K. Sidthipong, J. Tang, M. Li, T. Koyano, T. Kowithayakorn, K. Sumiyoshi, T. Ukaji, and K. Umezawa: Inhibition of NF- $\kappa$ B and cellular invasion by novel flavonoid desmal in ovarian carcinoma cells. *Heterocycles* 92: 353-360, 2016.

82. W. Seubwai, K. Vaeteewoottacharn, R. Kraiklang, K. Umezawa, S. Okada and S. Wongkham: Inhibition of NF- $\kappa$ B activity enhances sensitivity to anticancer drugs in cholangiocarcinoma cells. *Oncology Research* 23: 21-28, 2016.

83. M. El-Salhy and K. Umezawa: Treatment with novel AP-1 and NF- $\kappa$ B inhibitors restores the colonic endocrine cells to normal levels in rats with DSS-induced colitis. *International J. Molecular Medicine* DOI: 10.3892/ijmm.2016.2481.

84. M. El-Salhy and K. Umezawa: Anti-inflammatory effects of novel AP-1 and NF- $\kappa$ B inhibitors in dextran-sulfate-sodium-induced colitis in rats. *International J. Mol. Med.* DOI: 10.3892/ijmm.2016.2560.

85. T. Okamoto, Y. Ozawa, M. Kamoshita, H. Osada, E. Toda, T. Kurihara, N. Nagai, K. Umezawa and K. Tsubota: The neuroprotective effect of rapamycin as a modulator of the mTOR-NF- $\kappa$ B axis during retinal Inflammation. PLOS One published 15 Jan 2016 10.1371/journal.pone.0146517.
86. M. Hirasawa, K. Takubo, H. Osada, S. Miyake, E. Toda, M. Endo, K. Umezawa, K. Tsubota, Y. Oike and Y. Ozawa: Angiopoietin-like protein 2 is a multistep regulator of inflammatory neovascularization in a murine model of age-related macular degeneration. J. Biol. Chem. 291: 7373-7385, 2016. doi:10.1074/jbc.M115.710186.
87. M. Murahashi, S. Simizu, M. Morioka and K. Umezawa: Identification of poly(rC) binding protein 2 (PCBP2) as a target protein of immunosuppressive agent 15-deoxyspergualin. Biochem. Biophys. Res. Commun. 476: 445-449, 2016.
88. M. El-Salhy and K. Umezawa: Effects of AP-1 and NF-kappa B inhibitors on colonic endocrine cells in rats with TNBS-induced colitis. Molecular Medicine Reports 14: 1515-1522, 2016.
89. M. Morioka, K. Kato, and K. Umezawa: Design and synthesis of 15-deoxyspergualin-biotin conjugates as novel binding probes for target protein screening. J. Antibiotics 69: 574-578, 2016.
90. S. K. Gantsev, K. Umezawa, V. S. Vagapova, K. S. Gantsev, S. V. Solomenny, S. R. Kzyrgalin, R. S. Yamidanov, E. A. Gantseva: Calcification of peritoneum and peritoneal fluid perfusion malfunction in carcinomatosis of serous membranes of peritoneal cavity. Journal of Cancer Research & Therapy 4: 38-41, 2016.
91. M. El-Salhy, T. Mazzawi, K. Umezawa and O. H. Jilja: Enteroendocrine cells, stem cells and differentiation progenitors in rats with TNBS-induced colitis. International J. Mol. Med. DOI: 10.3892/ijmm.2016.2787.
92. S. Katsuyama, K. Sugino, Y. Sasazawa, Y. Nakano, H. Aono, K. Morishita, M. Kawatani, K. Umezawa, H. Osada and S. Simizu: Identification of a novel compound that inhibits osteoclastogenesis by suppressing nucleoside transporters. FEBS Letters 590: 1152–1162, 2016.

93. J. T. Burgess, E. Bolderson, M. N. Adams, A.-M. Baird, S.-D. Zhang, K. J. Gately, K. Umezawa, K. J. O'Byrne, and D. J. Richard: Activation and cleavage of SASH1 by Caspase-3 mediates an apoptotic response. *Cell Death Disease* 7: e7460, 2016.
94. M. Kawaguchi, K. Yamamoto, A. Kanemaru, H. Tanaka, K. Umezawa, T. Fukushima, H. Kataoka: Inhibition of nuclear factor- $\kappa$ B signaling suppresses Spint-1-deletion-induced tumor susceptibility in the ApcMin/+ mode. *Oncotarget* 7 (42): 68614-68622, 2016.
95. N. Ichikawa, K. Yamashita, F. Funakoshi, S. Ichihara, M. Fukai, M. Ogura, N. Kobayashi, M. Zaito, Y. Yoshida, S. Shibasaki, Y. Koshizuka, Y. Tsunetoshi, M. Sato, T. Einama, M. Ozaki, K. Umezawa, T. Suzuki and S. Todo: Novel anti-inflammatory agent 3-[(dodecylthiocarbonyl)-methyl]-glutarimide ameliorates murine models of inflammatory bowel disease. *Inflammation Research* 65: 245-260, 2016.
96. P. Sosińska, B. Maćkowiak, R. Staniszewski, K. Umezawa and A. Bręborowicz: Inhibition of NF- $\kappa$ B with dehydroxyepoxyquinomicin modifies function of human peritoneal mesothelial cells. *American Journal of Translational Research* 8: 5756-5765, 2016.
97. J. A. Pezuk, G. M. Roberto and K. Umezawa and M.S. Brassesco: DTCM-glutarimide hinders growth of childhood leukemia cells but fails to improve the efficacy of commonly used chemotherapeutic agents. *Current Bioactive Compounds* 13: 41-46, 2016.
98. K. Sidthipong, J. Ma, W. L. Yu, Y. F. Wang, S. Kobayashi, S. Kishino, N. Koide, T. Yokochi, K. Kato, S. Okada and K. Umezawa: Rational design, synthesis and in vitro evaluation of novel exo-methylene butyrolactone salicyloylamide as NF- $\kappa$ B inhibitor. *Bioorg. Med. Chem. Lett.* 27: 562-566, 2017.
99. T. Ikezoe, J. Yang, C. Nishioka, K. Umezawa and A. Yokoyama: Thrombomodulin blocks calcineurin inhibitor-induced vascular permeability via inhibition of Src/VE-cadherin axis. *Bone Marrow Transplantation* 52: 245–251, 2017.
100. T. Ukaji, Y. Lin, S. Okada and K. Umezawa: Inhibition of MMP-2-mediated cellular invasion by NF- $\kappa$ B inhibitor DHMEQ in 3D culture of breast carcinoma

MDA-MB-231 cells: A model for early phase of metastasis. *Biochem. Biophys. Res. Commun.* 485: 76-81, 2017..

101. M. El-Salhy, K. Umezawa, J. G. Hatlebakk and O. H. Gilja: Abnormal differentiation of stem cells into enteroendocrine cells in rats with DSS-induced colitis. *Mol. Med. Reports* 15: 2106-2112, 2017.

102. X. Jiang, B. Wei, Y. Lan, C. Dai, Y. Gu, J. Ma, X. Liu, K. Umezawa and Y. Zhang: External application of NF- $\kappa$ B inhibitor DHMEQ suppresses development of atopic dermatitis-like lesions induced with DNCB/OX in BALB/c mice. *Immunopharmacology and Immunotoxicology* 39:3, 157-164. 2017.

103. L. Wang, M. Li, J. Tang, Y. Y. Lin, K. Sidthipong, N. Sumida, N. Kushida and K. Umezawa: Novel p-terphenyl glycoside with a rare 2,6-dideoxy- hexopyranose moiety from *Actinomyces* strain SF2911 that inhibits cancer cell migration. *J. Antibiot.* 70: 987-990, 2017.

104. Y. Nakade, K. Sakamoto, T. Yamauchi, Tadahisa Inoue, Y. Kobayashi, T. Yamamoto, N. Ishii, T. Ohashi; Y. Sumida; K. Ito, H. Nakao, Y. Fukuzawa, K. Umezawa and M. Yoneda: Conophylline inhibits non-alcoholic steatohepatitis in mice. *PLOS One* 2017 Jun 8;12(6):e0178436.

105. 梅澤一夫 : カナマイシン耐性機構の解明とケミカルバイオロジー。 *Japanese Journal of Antibiotics* 70: 351-354, 2017.

106. C-P. Simon-Gabriel, K. Foerster, M. Benkisser-Petersen, D. Bleckmann, N. Thornton, K. Umezawa, S. Decker, C. Dierks, M. Burger, H. Veelken, R. Claus, J. Duyster, K. Zirlik: The microenvironmental stromal cells abrogate NF- $\kappa$ B inhibitor induced apoptosis in chronic lymphocytic leukemia. *Hematologica* November 2017 : haematol.2017.165381 Doi:10.3324/haematol.2017.165381.

107. T. Ukaji, N. Koide, Y. Lin, K. Banno, S. Gantsev and K. Umezawa: Molecular design of sugar-free migracin analog migracinal that inhibits ovarian cancer cell migration and invasion. *Creative Surgery and Oncology* 7 (4): 16-20, 2017. DOI:10.24060/2076-3093- 2017-7-4-16-20.

108. T. Fujii, N. Fujita, S. Suzuki, K. Watanabe, T. Tsuji, K. Ishii, T. Takaki, K. Umezawa, T. Miyamoto, K. Horiuchi, M. Matsumoto, M. Nakamura: The unfolded protein response mediated by PERK is casually related to the pathogenesis of intervertebral disc degeneration. *Journal of Orthopaedic Research* 36: 1334-1345, 2017. Version of Record online: 28 Nov 2017, DOI: 10.1002/jor.23787.
109. K. Umezawa, I. Kojima, S. Simizu, Y. Lin, H. Fukatsu, N. Koide, Y. Nakade and M. Yoneda: Therapeutic activity of plant-derived alkaloid conophylline on metabolic syndrome and neurodegenerative disease models (Review). *Human Cell* 31: 95-101, 2018.
110. Y. Lin, T. Ukaji, N. Koide and K. Umezawa: Inhibition of late and early phases of cancer metastasis by NF- $\kappa$ B inhibitor DHMEQ derived from microbial bioactive metabolite epoxyquinomicin: A review. *Int. J. Mol. Sci.* 2018, 19, 729; doi:10.3390/ijms19030729
111. G. B. M. Roberto, H. H. Paiva, L. E. B. deSouza, J. A. Pezuk, G. M. Vieira, H. F. deOliveira, K. Umezawa, L. G. Tone and M. S. Brassesco: DTCM-glutarimide delays growth and radiosensitizes glioblastoma. *Anti-cancer Agents in Medicinal Chemistry* 18, 2018, DOI:10.2174/1871520618666180423105740.
112. H. Fukatsu, N. Koide, S. Tada-Oikawa, K. Izuoka, A. Ikegami, S. Ichihara, T. Ukaji, N. Morita, Y. Naiki, T. Komatsu and K. Umezawa: NF- $\kappa$ B inhibitor DHMEQ inhibits titanium dioxide nanoparticle-induced interleukin-1 $\beta$  production: Inhibition of PM2.5-induced inflammation model. *Molecular Medicine Reports* 18: 5279-5285, 2018. DOI:10.3892/mmr.2018.9533.
113. X. Jiang, H. He, Z. Xie, H. Wen, X. Li, Xin Li, J. Ma, K. Umezawa and Y. Zhang: Dehydroxymethylepoxyquinomicin suppresses atopic dermatitis-like lesions in a stratum corneum-removed murine model through NF- $\kappa$ B inhibition. *Immunopharmacology and Immunotoxicology* 41: 32-39, 2019 DOI: 10.1080/08923973.2018.1510962
114. T. Tezuka, A. Ota, S. Karnan, K. Matsuura, K. Yokoo, Y. Hosokawa, D. Vigetti, A. Passi, S. Hatano, K. Umezawa and H. Watanabe: The plant alkaloid conophylline inhibits matrix formation of fibroblasts. *J. Biol. Chem.* 293: 20214 –20226, 2018.

115. T. Ohashi, Y. Nakade, M. Ibusuki, R Kitano, T. Yamauchi, S. Kimoto, T. Inoue, Y. Kobayashi, N. Ishii, Y. Sumida, K. Ito, H. Nakao, K. Umezawa and M. Yoneda: Conophylline inhibits high fat diet-induced non-alcoholic fatty liver disease in mice. PLOS One <https://doi.org/10.1371/journal.pone.0210068>, 2018.
116. N. Ishii, K. Araki, T. Yokobori, K. Hagiwara, G. Dolgormaa, T. Yamanaka, T. Handa, M. Tsukagoshi, T. Igarashi, A. Watanabe, N. Kubo, N. Harimoto, A. Masamune, K. Umezawa, H. Kuwano and K. Shirabe: Conophylline suppresses pancreatic cancer desmoplasia and cancer-promoting cytokines produced by cancer-associated fibroblasts. Cancer Science 10:334-344, 2019. DOI: 10.1111/cas.13874.
117. Y. Lin, Y. Chen, T. Ukaji, S. Okada and K. Umezawa: Isolation of ketomycin from *Actinomycetes* as an inhibitor of 2D and 3D cancer cell invasion. J. Antibiot. 72: 148-154, 2019.
118. Y. Ando, H. Keino, A. Kudo, A. Hitrakata, A. A. Okada and K. Umezawa: Anti-Inflammatory effect of dehydroxymethylepoxyquinomicin, a nuclear factor- $\kappa$ B inhibitor, on endotoxin-induced uveitis in rats in vivo and in vitro. Occular Immunology & Inflammation 28: 240-248, 2019, DOI: 10.1080/09273948.2019.1568502.
119. H. He, X. Gao, X. Wang, X. Li, X. Jiang, Z. Xie, K. Ma, J. Ma, K. Umezawa and Y. Zhang: Comparison of anti-atopic dermatitis activities between DHMEQ and tacrolimus ointments in mouse model without stratum corneum. International Immunopharmacology 71:43-51, June 2019. <https://doi.org/10.1016/j.intimp.2019.03.015>
120. K. Shiraiwa, M. Mitsutake, Y. Nakazawa, T. Ogi, K. Suzuki, V. Saenko, K. Umezawa, S. Yamashita and K. Tsukamoto: The JAK/STAT3 and NF- $\kappa$ B signaling pathways regulate cancer stem cell properties in anaplastic thyroid cancer cells. Thyroid 29: 674-682, 2019 DOI: 10.1089/thy.2018.0212
121. G. A. Bonafé, J. S. dos Santos, J. V. Ziegler, K. Umezawa, M. L. Ribeiro, T. Rocha and M. M. Ortega: Growth inhibitory effects of dipotassium glycyrrhizinate in glioblastoma cell lines by targeting microRNAs through the NF- $\kappa$ B signaling pathway. Frontiers in Cellular Neuroscience Volume 13: Article 216doi: 10.3389/fncel.2019.00216.



122. A. Breborowicz and K. Umezawa: Causes and mechanisms of peritoneal fibrosis and possible application of NF- $\kappa$ B inhibitor for prevention and treatment. *Journal of Medical Science* 88: 102-111, 2019 DOI: <https://doi.org/10.20883/jms.352>.
123. H. Fu, M. Alabdullah, J. Großmann, F. Spieler, R. Abdosh, V. Lutz, K. Kalies, K. Knopp, K. Rieckmann, S. Koch, M. Nutsias, C. Pilowski, J. Dutzmann D. Sedding, S. Hüttelmaier, K. Umezawa, K. Werdan and H. Loppnow: The differential statin effect on cytokine production of monocytes or macrophages is mediated by differential geranylgeranylation-dependent Rac1 activation. *Cell Death and Diseases* (2019) 10:880 <https://doi.org/10.1038/s41419-019-2109-9>.
124. S.-L. Ryan, S. Beard, M. P. Barr, K. Umezawa, S. Heavey, P. Godwin, S. G. Gray, D. Cormican, S. P. Finn, K. A. Gately, A. M. Davies, E. W. Thompson, D. J. Richard, K. J. O'Byrne, M. N. Adams, A.-M. Baird: Targeting NF- $\kappa$ B-mediated inflammatory pathways in cisplatin-resistant NSCLC. *Lung Cancer* 135: 217-227, 2019. doi: 10.1016/j.lungcan.2019.07.006.
125. K. Umezawa and Y. Lin: Inhibition of matrix metalloproteinase expression and cellular invasion by NF- $\kappa$ B inhibitors of microbial origin. *BBA-Proteins and Proteomics* 1868(6):140412. doi: 10.1016/j.bbapap.2020.140412.
126. L. Wang, M. Li, Y. Lin, S. Du, Z. Liu, J. Ju, H. Suzuki, M. Sawada and K. Umezawa: Inhibition of cellular inflammatory mediator production and amelioration of learning deficit in flies by deep sea *Aspergillus*-derived cyclophenin. *J. Antibiot.* 73: 622-629, 2020. DOI: 10.1038/s41429-020-0302-9.
127. C. Saengboonmee, C. Phoomak, S. Supabphol, K. R. Covington, O. Hampton, C. Wongkham, R. A. Gibbs, K. Umezawa, W. Seubwai, M.-C. Gingras, S. Wongkham: NF- $\kappa$ B and STAT3 co-operation enhances high glucose induced aggressiveness of cholangiocarcinoma cells. *Life Sciences* 262: 118548, 2020, <https://doi.org/10.1016/j.lfs.2020.118548>.
128. Y. Ando, Y. Sato, A. Kudo, T. Watanabe, A. Hirakata, A. A. Okada, K. Umezawa and H. Keino: Anti-inflammatory effects of the NF- $\kappa$ B inhibitor dehydroxymethylepoxyquinomicin on ARPE-19 cells. *Molecular Medicine Reports* 22:

582-590, 2020.

129. Y. Lin, N. Sugiura, J. Ma and K. Umezawa: Cellular anti-inflammatory activity of novel I- $\kappa$ B kinase inhibitor ketomycin. In Special Issue “Nonsteroidal anti-inflammatory drug” *Pharmaceutical Science and Biomedical Analysis Journal* 3(1): 122, 2020.

130. S. Morita, K. Shinoda, T. Yoshida, M. Shimoda, Y. Kanno, R. Mizuno, H. Kono, H. Asanuma, K. Nakagawa, K. Umezawa, M. Oya: Dehydroxymethylepoxyquinomicin, a novel nuclear factor- $\kappa$ B inhibitor, prevents the development of cyclosporine A nephrotoxicity in a rat model. *BMC Pharmacology and Toxicology* (2020) 21:60 <https://doi.org/10.1186/s40360-020-00432-3>.

131. X. Lu, J. He, Y. Wu, N. Du, X. Li, J. Ju, Z. Hu, K. Umezawa and L. Wang: Isolation and characterization of anti-inflammatory and antioxidant components from deep marine-derived fungus *Myrothecium* sp. Bzo-1062. *Mar. Drugs* 2020, 18(12), 597; <https://doi.org/10.3390/md18120597>.

132. K. Umezawa, A. Breborowicz, and S. Gantsev: Anticancer activity of novel NF- $\kappa$ B inhibitor DHMEQ by intraperitoneal administration. *Oncology Research* 28: 541-550, 2020 doi: <https://doi.org/10.3727/096504020X15929100013698>.

133. M. F. Candido, G. C. Baldissera, M. Medeiros, K. Umezawa and M. S. Brassesco: NF- $\kappa$ B inhibition by DHMEQ: in vitro antiproliferative effects on pilocytic astrocytoma and concise review of the current literature. *Child's Nervous System* 36: 2675–2684, 2020 <https://doi.org/10.1007/s00381-020-04625-3>.

134. L. Todorovic, G. Stamenkovic, B. V. Tadic, K. Umezawa, A. Bozovic, S. Yamashita and B. Stanojevic: Synergistic effect of 17-allylamino-17-demethoxygeldanamycin with dehydroxymethylepoxyquinomicin on the human anaplastic thyroid carcinoma cell line KTC2. *Archives of Biological Sciences* 2020; <https://doi.org/10.2298/ABS201010055T>.

135. K. Umezawa and K. Shirabe: Direct and indirect anticancer activity of plant-derived alkaloid conophylline. *Critical Reviews in Oncogenesis* 26: 67–72, 2021. DOI: 10.1615/CritRevOncog.2020034129.

136. L. Wang and K. Umezawa: Cellular signal transduction and their inhibitors from deep-sea organisms. (Review) *Marine Drugs* 2021, 19, 205. <https://doi.org/10.3390/md19040205>.
137. T. Yamanaka, N. Harimoto, T. Yokobori, R. Muranushi, K. Hoshino, K. Hagiwara, D. Gantumur, T. Handa, N. Ishii, M. Tsukagoshi, T. Igarashi, A. Watanabe, N. Kubo, K. Araki, K. Umezawa and K. Shirabe: Conophylline inhibits hepatocellular carcinoma by inhibiting activated cancer-associated fibroblasts through suppression of G protein-coupled receptor 68. *Molecular Cancer Therapeutics* 20:1019-1028, 2021; DOI: 10.1158/1535-7163.MCT-20-0150
138. Y. Lin, K. Sidthipong, J. Ma, N. Koide, K. Umezawa and T. Kubota: Designed NF- $\kappa$ B inhibitor, DHMEQ, inhibits KISS1R-mediated invasion and increases drug-sensitivity in mouse plasmacytoma SP2/0 cells. *Experimental and Therapeutic Medicine* 22: 1092,2021. DOI: 10.3892/etm.2021.10526
139. J. Ma, Y. Zhang, T. Sugai, T. Kubota, H. Keino, M. El-Salhy, M. Ozaki and K. Umezawa: Inhibition of cellular and animal inflammatory disease models by NF- $\kappa$ B inhibitor DHMEQ. *Cells* 2021,10,2271. <https://doi.org/10.3390/cells10092271>.
140. H Fujisaki, Y. Nakano, S. Matsuda, K. Suzuki, O. Itano, M. Tanaka, S. Hori, Y. Abe, H. Yagi, M. Kitago, T. Konno, K. Ishihara, K. Ohno, S. Kishino, K. Umezawa, and Yuko Kitagawa: Intravenous administration of dehydroxymethylepoxyquinomicin with polymer enhances the inhibition of pancreatic carcinoma growth in mice. *Anticancer Res.* 41: 6003-6012, 2021. doi:10.21873/anticancerres.15419.
141. M. Michalak, M. S. Lach, S. Borska, B. Nowakowski, K. Umezawa, W. M. Suchorska: DHMEQ enhances the cytotoxic effect of cisplatin and carboplatin in ovarian cancer cell lines. *Am. J. Cancer Res.* 11: 6024-6041, 2021. [www.ajcr.us](http://www.ajcr.us) /ISSN:2156-6976/ajcr0086912.
142. K. Ito, A. Okumura, J. S. Takeuchi, K. Watashi, R. Inoue, T. Yamauchi, K. Sakamoto, Y. Yamashita, Y. Iguchi, M. Une, T. Wakita, K. Umezawa and M. Yoneda: Dual agonist of farnesoid X receptor and G protein-coupled receptor TGR5 inhibits hepatitis B virus Infection in vitro and in vivo. *Hepatology* 74: 83-98, 2021.

143. K. Umezawa (Editor): Natural Product from the Deep Sea. Book, MDPI, 2022.
144. R. Nakagawa, H. Tateishi, M. O. Radwan, T. Chinen, H. Ciftci, K. Iwamaru, N. Baba, Y. Tominaga, R. Koga, T. Toma, J. Inoue, K. Umezawa, M. Fujita, and M. Otsuka: A new 1,2-naphthoquinone derivative with anti-lung cancer activity. Chem. Pharm. Bull. 70: 477-482, 2022. [Doi.org/10.1248/cpb.c21-01087](https://doi.org/10.1248/cpb.c21-01087).
145. S. Kojima, M. Hakamata, T. Asanuma, R. Suzuk, J. Tsuruda, T. Nonoyama, Y. Lin, H. Fukatsu, N. Koide and K. Umezawa: Cellular anti-inflammatory and anti-oxidant activities of bamboo *Sasa albomarginata* leaf extract and its constituent coumaric acid methyl ester. The Scientific World Journal 2022: Article number 8454865. [doi.org/10.1155/2022/8454865](https://doi.org/10.1155/2022/8454865)
146. Y. Wu, J. Shen, L. Wang, Y. Lin, S. Kojima, S. Okada, K. Umezawa: Isolation of the anti-inflammatory agent myceliostatin from a methionine-enriched culture of *Myceliophthora thermophila* ATCC 42464. J. Nat Prod. February 2023 <https://doi.org/10.1021/acs.jnatprod.2c00811>
147. M. S. Brassesco, G. M. Roberto, L. E. Delsin, G. C. Baldissera, M. Medeiros, K. Umezawa, L. G. Tone: A foretaste for pediatric glioblastoma therapy: targeting the NF- $\kappa$ B pathway with DHMEQ. Child's Nervous System February 2023, DOI: 10.1007/s00381-023-05878-4